Is a tablet containing 170mg of Pancreatin (Pancreatic Enzyme Replacement Therapy) the same as PERT (Pancreatic Enzyme Replacement Therapy)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is a 170mg Pancreatin Tablet the Same as PERT?

No, a tablet containing 170mg of pancreatin is not the same as prescription PERT and should not be used for treating exocrine pancreatic insufficiency. Over-the-counter pancreatic enzyme supplements are classified as dietary supplements only, with neither standardized dosing nor regulated efficacy, making their utility and safety unknown 1.

Why Over-the-Counter Pancreatin is Inadequate

Prescription PERT products are labeled based on their USP lipase content (typically ranging from 3,000 to 40,000 USP units per capsule), not by weight of pancreatin powder 1. The 170mg weight designation tells you nothing about the actual enzymatic activity, which is what matters clinically.

Key Differences Between OTC Pancreatin and Prescription PERT:

  • Lack of standardization: Over-the-counter enzyme preparations have no standardized or regulated dosing, making them ineffective for treating pancreatic insufficiency 1, 2
  • Unknown potency: The enzymatic activity (lipase, protease, amylase units) in OTC products is neither verified nor consistent between batches 1
  • No enteric coating: Most OTC preparations lack the pH-sensitive enteric coating that protects enzymes from gastric acid degradation and ensures release in the duodenum 3, 4
  • Inadequate dosing: Even if the 170mg contained some enzymatic activity, it would fall far short of the minimum recommended dose of 40,000 USP units of lipase per meal 1, 3

What Constitutes Proper PERT

All commercially available FDA-approved PERT products are of porcine origin and contain enteric-coated microspheres, beads, or microtablets 1, 3. These formulations include:

  • Creon (enteric-coated microspheres) 3
  • Zenpep (enteric-coated beads) 3
  • Pancreaze (enteric-coated microtablets) 3
  • Pertzye (enteric-coated microspheres) 3

Minimum Dosing Requirements:

  • Adults require at least 40,000 USP units of lipase per main meal 1, 3, 2
  • Adults require 20,000 USP units of lipase per snack (half the meal dose) 1, 3, 2
  • For chronic pancreatitis specifically, doses range from 20,000-50,000 PhU of lipase per main meal 1, 3

Clinical Consequences of Using Inadequate Preparations

Failure to provide proper PERT in adequate doses results in continuation of maldigestion symptoms, micro- or macro-nutritional deficiencies, poor quality of life, and increased mortality 1. The adverse sequelae include:

  • Persistent steatorrhea and gastrointestinal symptoms 1, 3
  • Fat-soluble vitamin deficiencies (A, D, E, K) 1, 3
  • Unintentional weight loss and protein malnutrition 1, 2
  • Reduced quality of life and survival, particularly in pancreatic cancer patients 1
  • Increased risk of osteoporosis from vitamin D and K deficiency 5

Common Pitfall to Avoid

Verify that patients are not using over-the-counter enzyme supplements instead of or in addition to prescription PERT, as this is a recognized cause of treatment failure 5. Research shows that even in insured US populations, only 30.4% of chronic pancreatitis patients and 21.9% of pancreatic cancer patients fill prescriptions for PERT, with even fewer receiving adequate doses 6.

Bottom Line

A 170mg pancreatin tablet is fundamentally different from prescription PERT in formulation, standardization, enzymatic potency, and clinical efficacy 1, 2. Patients with exocrine pancreatic insufficiency require FDA-approved, enteric-coated PERT products dosed based on USP lipase units, not milligrams of pancreatin powder.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Pancreatic Enzyme Replacement Therapy in Patients with Chronic Pancreatitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Optimal Timing and Dosing of Pancreatic Enzyme Replacement Therapy (PERT)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Properties of different pancreatin preparations used in pancreatic exocrine insufficiency.

European journal of gastroenterology & hepatology, 2009

Guideline

Optimizing Pancreatic Enzyme Replacement Therapy (PERT) with Zenpep

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.